Norwegian Contrasts
IC Targets AS is a life-science company dedicated to the development of manganese-based MRI contrast agents and new methods that will improve diagnostic imaging
Norwegian Contrasts
IC Targets AS is a life-science company dedicated to the development of manganese-based MRI contrast agents and new methods that will improve diagnostic imaging
Menu
Norwegian Contrasts
IC Targets AS is a life-science company dedicated to the development of manganese-based MRI contrast agents and new methods that will improve diagnostic imaging
Menu
Norwegian Contrasts
IC Targets AS is a life-science company dedicated to the development of manganese-based MRI contrast agents and new methods that will improve diagnostic imaging
What we do
Mangafodipir is a novel MRI contrast agent in development for improved diagnostics of heart, liver and pancreas diseases.
Recent news
Jul 13, 2026
IC Targets AS receives Notice of Allowance for cardiac MRI patent
Jul 13, 2026
IC Targets AS receives Notice of Allowance for cardiac MRI patent
Jul 13, 2026
IC Targets AS receives Notice of Allowance for cardiac MRI patent
Dec 20, 2025
IC Targets AS completes last patient visit in Phase 2A mangafodipir trial
Dec 20, 2025
IC Targets AS completes last patient visit in Phase 2A mangafodipir trial
Dec 20, 2025
IC Targets AS completes last patient visit in Phase 2A mangafodipir trial
Dec 11, 2025
IC Targets AS filed a new patent application on improved detection of heart disease
Dec 11, 2025
IC Targets AS filed a new patent application on improved detection of heart disease
Dec 11, 2025
IC Targets AS filed a new patent application on improved detection of heart disease
© 2025
Visiting address
c/o ParalleIl, Lørenveien 73A, 0585 Oslo
Contact us
Visiting address
c/o ParalleIl, Lørenveien 73A, 0585 Oslo
Contact us
Visiting address
c/o ParalleIl, Lørenveien 73A, 0585 Oslo
Contact us
© 2025
Visiting address
c/o ParalleIl, Lørenveien 73A, 0585 Oslo
Contact us